While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.
Tag Archive for: Amgen
Mirati Therapeutics said on Friday the European medicines regulator’s panel has recommended approval of its treatment for a type of lung cancer.
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission’s decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horizon Therapeutics.
The Department of Health and Human Services in a court filing last week said that the blockbuster treatment could be “deselected” from the drug price negotiation list, given the recent approval of Amgen’s Stelara biosimilar.
The company, which earlier this month acquired Horizon Therapeutics for $27.8 billion, said on Tuesday its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
In its fourth round of layoffs this year, the California-based biopharma company is letting go of 350 former Horizon Therapeutics staff whose roles overlap with existing positions at Amgen, according to reports.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
With the settlement of a big acquisition behind them and a strong portfolio of therapeutics that continues to expand, hopes for smooth sailing are on the horizon.
Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.
